Finance

Lists
500660:BOM
GlaxoSmithKline Pharmaceuticals Ltd
2 567,25 ₹
+1,75%
(+44,25) 1D
16 հոկ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500660...
Open
2 527,25 ₹
High
2 572,40 ₹
Low
2 527,25 ₹
Mkt. cap
434,71 մլրդ
Avg. vol.
5,03 հզր
Volume
2,37 հզր
Dividend
2,22%
Quarterly dividend
14,25 ₹
Ex-dividend date
29 մյս, 2026 թ.
P/E ratio
40,72
52-wk high
3 121,10 ₹
52-wk low
2 088,00 ₹
EPS
63,05 ₹
Shares outstanding
169,41 մլն
No. of employees
3 հզր
Open
2 527,25 ₹
High
2 572,40 ₹
Low
2 527,25 ₹
Mkt. cap
434,71 մլրդ
Avg. vol.
5,03 հզր
Volume
2,37 հզր
Dividend
2,22%
Quarterly dividend
14,25 ₹
Ex-dividend date
29 մյս, 2026 թ.
P/E ratio
40,72
52-wk high
3 121,10 ₹
52-wk low
2 088,00 ₹
EPS
63,05 ₹
Shares outstanding
169,41 մլն
No. of employees
3 հզր
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3,1 հզր
Founded13 նոյ, 1924 թ.
Headquarters-
Sector-
Last report
03 օգս, 2026 թ.
Fiscal period
Q1 2027
14,00 ₹ / 13,90 ₹
+0,72%beat
Revenue / Est. (INR)
9,38 մլրդ / 9,11 մլրդ
+3,00%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
9,80 մլրդ
10,41 մլրդ
9,95 մլրդ
9,38 մլրդ
Cost of goods sold
3,56 մլրդ
3,64 մլրդ
3,69 մլրդ
3,28 մլրդ
Cost of revenue
3,56 մլրդ
3,64 մլրդ
3,69 մլրդ
3,28 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,38 մլրդ
1,52 մլրդ
2,95 մլրդ
1,59 մլրդ
Operating expense
3,06 մլրդ
3,26 մլրդ
2,84 մլրդ
3,31 մլրդ
Total operating expenses
6,62 մլրդ
6,90 մլրդ
6,53 մլրդ
6,59 մլրդ
Operating income
3,18 մլրդ
3,51 մլրդ
3,43 մլրդ
2,80 մլրդ
Other non operating income
335,70 մլն
321,20 մլն
-1,09 մլրդ
437,60 մլն
EBT including unusual items
3,54 մլրդ
4,00 մլրդ
3,73 մլրդ
3,22 մլրդ
EBT excluding unusual items
3,51 մլրդ
3,82 մլրդ
2,94 մլրդ
3,22 մլրդ
Income tax expense
965,10 մլն
1,04 մլրդ
952,41 մլն
852,70 մլն
Effective tax rate
27,26%
26,08%
25,53%
26,44%
Other operating expenses
1,51 մլրդ
1,54 մլրդ
-236,82 մլն
1,56 մլրդ
Net income
2,57 մլրդ
2,96 մլրդ
2,78 մլրդ
2,37 մլրդ
Net profit margin
26,28%
28,39%
27,92%
25,27%
Earnings per share
-
-
-
14,00
Interest and investment income
-
-
657,30 մլն
-
Interest expense
-5,10 մլն
-11,90 մլն
-6,12 մլն
-9,70 մլն
Net interest expenses
-5,10 մլն
-11,90 մլն
651,18 մլն
-9,70 մլն
Depreciation and amortization charges
174,30 մլն
203,20 մլն
131,74 մլն
158,40 մլն
EBITDA
3,35 մլրդ
3,61 մլրդ
3,52 մլրդ
2,89 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps